Onco-Innovations Stock Price, News & Analysis

Onco-Innovations (OTCQB:ONNVF) appointed Jared Rushton to its Board of Directors, effective October 30, 2025, replacing Zachary Stadnyk.

Mr. Rushton brings over a decade of public markets experience in corporate development, strategic advisory and capital markets planning across mining, cannabis and biotech sectors.

The company also engaged MCS Market Communication Service GmbH for online marketing services through December 15, 2025 (or until budget exhaustion) and paid EUR 600,000 in consideration; no securities were issued to MCS. Services include Google Ads, native advertising, campaign creation, and analytics.

Onco-Innovations (OTCQB:ONNVF) closed a non-brokered private placement on October 27, 2025, issuing 1,428,570 units at $1.40 per unit for aggregate gross proceeds of $2,000,000. Each unit comprises one common share and one-half of one warrant; warrants are exercisable at $2.00 per share for 36 months. The company paid finders $119,999.94 and issued 85,714 warrants, and issued 14,286 administrative shares for services. Proceeds are for general corporate and working capital purposes, including operational, R&D and investor relations objectives. All securities are subject to a four-month-and-one-day statutory hold and are not registered for sale in the United States.

Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 1,428,572 units at $1.40 per unit to raise up to $2,000,000. Each unit includes one common share and one-half of a warrant, with each whole warrant exercisable at $2.00 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of shares sold and may pay finders' fees or issue finders' warrants on similar terms. Proceeds are for general corporate and R&D purposes. Closing is subject to regulatory approvals and issued securities carry a four-month-and-one-day hold. The company also appointed Christopher Gulka to the board, succeeding Graydon Bensler.

Onco-Innovations (OTCQB:ONNVF) has announced the initiation of laboratory work for its IND-enabling program through Nucro-Technics, focusing on their Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology.

The program centers on developing and validating analytical methods using liquid chromatography-mass spectrometry (LC-MS) to measure the PNKP Technology (A83B4C63) in animal model plasma and its polymer-based nanoparticle delivery system. These methods will support future toxicology and pharmacokinetics studies under GLP standards, required for FDA and Health Canada regulatory submissions.

The analytical tools will enable tracking of both free and encapsulated forms of the compound, providing crucial data on stability, metabolism, and drug exposure in vivo, essential for advancing towards human clinical trials.

Onco-Innovations (OTCQB:ONNVF) has appointed Dr. Michael Lock, Professor in Oncology and Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock brings extensive experience in clinical trial design, translational oncology, and multidisciplinary cancer care.

Dr. Lock's distinguished career includes leadership roles as Chair of Radiation Oncology, Chief of Division of Radiation Oncology, and Medical Director of the London Regional Cancer Program. His international contributions include work with the IAEA, UN, and WHO. The appointment aims to support Onco's development of novel therapies, particularly its PNKP inhibitor program.

Additionally, the company's Board has approved a grant of 1,155,000 Restricted Share Units to directors, officers, and consultants.

Onco-Innovations (OTCQB:ONNVF) has initiated manufacturing activities with Dalton Pharma Services for its proprietary nanoparticle formulation, PEO-b-PBz-CL. This formulation is a crucial component of Onco's drug delivery platform designed to work with their PNKP inhibitor.

The manufacturing process will involve scale-up activities from 10 grams to 350 grams, focusing on optimization and establishing reproducible synthesis methods. Dalton will ensure the formulation meets quality specifications for purity, molecular weight, and residual solvent levels, while generating necessary analytical data for regulatory filings and future GMP manufacturing.

Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health Corp., will chair and lead the fourth roundtable of Colorectal Cancer Canada's (CRC) Catalysts: Innovating for Tomorrow Series this fall. The virtual event will focus on data innovation and digital trust in oncology.

The roundtable will be chaired by Dr. Paul Arora, with expert speakers including Dr. Steve Jones from BC Cancer, Dr. Winson Cheung from the University of Calgary, and Inka Health Co-Founder Alind Gupta. The discussion will explore the integration of artificial intelligence, secure data sharing, and the application of emerging data sources in precision medicine.

Onco-Innovations (CBOE CA:ONCO) has appointed Dr. John Mackey, Professor Emeritus in Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Mackey brings extensive experience in oncology, clinical trials, and drug development, having previously served as Director of the Clinical Trial Unit at Cross Cancer Institute and Executive Director of TRIO.

Dr. Mackey's credentials include co-founding Pacylex Pharmaceuticals, serving as CEO of illumiSonics, holding 12 patents, and co-authoring over 300 peer-reviewed publications. His expertise will support Onco's PNKP inhibitor program development, particularly in clinical strategy and trial methodology.

Onco-Innovations (OTCQB:ONNVF) has announced that over 90% of its $0.60 common share purchase warrants have been successfully exercised over an eight-month period. This high conversion rate has resulted in additional capital inflow for the company through non-dilutive financing.

CEO Thomas O'Shaughnessy highlighted that the significant warrant exercise rate demonstrates strong shareholder confidence in the company's strategic direction and validates their ability to generate internal capital.